Stromedix LLC develops antibody drugs targeting fibrotic organ failure, with anti-fibrotic activity demonstrated in preclinical models of lung, kidney, and liver diseases
Stromedix LLC develops antibody drugs targeting fibrotic organ failure, with anti-fibrotic activity demonstrated in preclinical models of lung, kidney, and liver diseases.